Theravance Biopharma (TBPH) Return on Invested Capital (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Return on Invested Capital data on file, last reported at 0.0% in Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.0%, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 3.0% YoY), and the FY2025 annual result was 0.0%, down 2.0% from the prior year.
• Return on Invested Capital retreated to 0.0% in Q1 2026 per TBPH's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.02% in Q4 2024 and troughed at 0.03% in Q1 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2022 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Return on Invested Capital declined 3 bps in 2022, then grew 3 bps in 2024.
• A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2022, then tumbled by 37 bps to 0.0% in 2023, then surged by 920 bps to 0.02% in 2024, then slumped by 100 bps to 0.0% in 2025, then plunged by 110 bps to 0.0% in 2026.
• Business Quant data shows TBPH's Return on Invested Capital at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.